Insider Buying: Repro-Med Systems (OTCMKTS:REPR) Director Buys 63,110 Shares of Stock

Repro-Med Systems (OTCMKTS:REPR) Director Joseph M. Jr. Manko bought 63,110 shares of Repro-Med Systems stock in a transaction dated Friday, March 16th. The shares were acquired at an average price of $1.29 per share, with a total value of $81,411.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of OTCMKTS REPR opened at $1.37 on Monday. Repro-Med Systems has a 12 month low of $0.34 and a 12 month high of $1.44.

COPYRIGHT VIOLATION NOTICE: “Insider Buying: Repro-Med Systems (OTCMKTS:REPR) Director Buys 63,110 Shares of Stock” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/09/repro-med-systems-inc-repr-director-joseph-m-jr-manko-buys-63110-shares-of-stock.html.

About Repro-Med Systems

Repro Med Systems, Inc designs, manufactures, and markets proprietary portable medical devices and supplies primarily for the ambulatory infusion market and emergency medical applications worldwide. The company offers mechanical infusion product FREEDOM infusion systems, which include the FREEDOM60 syringe infusion driver, the FreedomEdge syringe infusion driver, HIgH-Flo subcutaneous safety needle sets, RMS precision flow rate tubing, and RMS precision flow rate controller, as well as medical suction product RES-Q-VAC, a portable medical suction system.

Insider Buying and Selling by Quarter for Repro-Med Systems (OTCMKTS:REPR)

Receive News & Ratings for Repro-Med Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repro-Med Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply